Literature DB >> 20609189

Impact of serum apolipoprotein A-IV as a marker of cardiovascular disease in maintenance hemodialysis patients.

Maho Omori1, Makoto Watanabe, Kei Matsumoto, Hirokazu Honda, Hiroaki Hattori, Tadao Akizawa.   

Abstract

The aim of this study was to investigate the relationship between serum apolipoprotein (apo) A-IV levels and markers for atherosclerosis, including carotid intima-media thickness (CIMT) and the ankle-brachial index (ABI), in hemodialysis patients. We performed a cross-sectional study involving 116 maintenance hemodialysis patients (70 males; median age, 64 years), measuring CIMT, ABI, the usual laboratory examinations, and serum apo A-IV before the dialysis session. The apo A-IV concentration was measured by a noncompetitive ELISA. Serum apo A-IV concentrations were significantly lower in hemodialysis patients with cardiovascular disease and plaque in the carotid artery. The apo A-IV level was positively associated with urea nitrogen and creatinine, and negatively associated with age, interleukin-6, the neutrophil/lymphocyte ratio, and maximum CIMT. Moreover, serum apo A-IV concentrations were significantly lower in the low ABI group. On logistic analysis, patients with high apo A-IV levels had a lower odds ratio for atherosclerosis (maximum CIMT > 1.0) and cardiovascular disease compared to patients with low apo A-IV levels. On stepwise multivariate regression analysis, the serum apo A-IV level was independently associated with creatinine, the neutrophil/lymphocyte ratio, and the maximum CIMT. Serum apo A-IV is associated with atherosclerotic lesions in hemodialysis patients. Apo A-IV levels may be useful for estimating the risk of cardiovascular disease in dialysis patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609189     DOI: 10.1111/j.1744-9987.2010.00809.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  8 in total

Review 1.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

2.  Age- and sex-associated plasma proteomic changes in growth hormone receptor gene-disrupted mice.

Authors:  Juan Ding; Darlene E Berryman; Adam Jara; John J Kopchick
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-12-07       Impact factor: 6.053

3.  Proteomics study of serum exosomes in Kawasaki disease patients with coronary artery aneurysms.

Authors:  Xiao-Fei Xie; Hong-Juan Chu; Yu-Fen Xu; Liang Hua; Zhou-Ping Wang; Ping Huang; Hong-Ling Jia; Li Zhang
Journal:  Cardiol J       Date:  2018-04-03       Impact factor: 2.737

4.  A genome-wide association meta-analysis on apolipoprotein A-IV concentrations.

Authors:  Claudia Lamina; Salome Friedel; Stefan Coassin; Rico Rueedi; Noha A Yousri; Ilkka Seppälä; Christian Gieger; Sebastian Schönherr; Lukas Forer; Gertraud Erhart; Barbara Kollerits; Pedro Marques-Vidal; Janina Ried; Gerard Waeber; Sven Bergmann; Doreen Dähnhardt; Andrea Stöckl; Stefan Kiechl; Olli T Raitakari; Mika Kähönen; Johann Willeit; Ludmilla Kedenko; Bernhard Paulweber; Annette Peters; Thomas Meitinger; Konstantin Strauch; Terho Lehtimäki; Steven C Hunt; Peter Vollenweider; Florian Kronenberg
Journal:  Hum Mol Genet       Date:  2016-07-12       Impact factor: 6.150

5.  Evaluating the Causal Relation of ApoA-IV with Disease-Related Traits - A Bidirectional Two-sample Mendelian Randomization Study.

Authors:  Salome Mack; Stefan Coassin; Julien Vaucher; Florian Kronenberg; Claudia Lamina
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

6.  Novel protein constituents of pathological ocular pseudoexfoliation syndrome deposits identified with mass spectrometry.

Authors:  Shiwani Sharma; Tim Chataway; Sonja Klebe; Kim Griggs; Sarah Martin; Nusha Chegeni; Alpana Dave; Tiger Zhou; Maurizio Ronci; Nicolas H Voelcker; Richard A Mills; Jamie E Craig
Journal:  Mol Vis       Date:  2018-12-28       Impact factor: 2.367

Review 7.  Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease.

Authors:  Cristiana-Elena Vlad; Liliana Foia; Roxana Popescu; Iuliu Ivanov; Mihaela Catalina Luca; Carmen Delianu; Vasilica Toma; Cristian Statescu; Ciprian Rezus; Laura Florea
Journal:  J Diabetes Res       Date:  2019-12-14       Impact factor: 4.011

8.  Apolipoprotein A-IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study.

Authors:  Johannes P Schwaiger; Barbara Kollerits; Inga Steinbrenner; Hansi Weissensteiner; Sebastian Schönherr; Lukas Forer; Fruzsina Kotsis; Claudia Lamina; Markus P Schneider; Ulla T Schultheiss; Christoph Wanner; Anna Köttgen; Kai-Uwe Eckardt; Florian Kronenberg
Journal:  J Intern Med       Date:  2022-01-04       Impact factor: 13.068

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.